
OR WAIT null SECS
At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.
Artificial intelligence (AI) tools for chronic obstructive pulmonary disease (COPD) diagnosis, remote monitoring, and posthospital care have clinical potential but still require validation before routine use, according to Jean Bourbeau, MD, professor of medicine at McGill University, in an interview with HCPLive at the CHEST 2026 Annual Meeting in Phoenix, Arizona.
The 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report added a new chapter on AI and emerging technologies in COPD. The chapter describes potential roles in diagnosis, assessment, and prediction of disease progression, along with clinical, data, ethical, and operational limitations.¹ Bourbeau said the GOLD 2027 report will build on this foundation, with a more detailed manuscript on AI currently under review.
“We have to make sure we are positioning AI in the right place because it is very exciting,” Bourbeau said. “But we also have to be careful, because there is still a lot of validation to be done.”
Bourbeau said he does not consider himself an AI expert and described this as useful because clinicians know where the gaps exist in practice. Some clinicians already use AI to record patient interviews and build visit documentation in the electronic health record, which frees time for direct patient care.
The electronic chart may also help clinicians recognize COPD earlier. Bourbeau described a future point-of-care role in which AI built into the chart helps clinicians identify what a patient needs, based on GOLD recommendations and guideline-based care.
Other applications remain investigational. Work is underway on CT scan biomarkers, where AI analysis could help distinguish COPD phenotypes, and on blood and voice biomarkers to support patient management. Bourbeau emphasized these approaches still require validation before clinical implementation.
Telehealth and home monitoring are another active area of research, including wearable devices such as rings used to detect exacerbations early. According to Bourbeau, these tools generate large volumes of heterogeneous data, more than any nurse or physician can realistically analyze, and clinicians are now swamped.
AI could turn these data into actionable information for the clinician, including early exacerbation signals and assessment of inhaler technique. Bourbeau again stressed the need for validation before these capabilities reach routine care.
He also highlighted the patient perspective, particularly education and the transition out of the hospital. Many communications with patients after discharge do not happen because of limited resources, and AI programs built on appropriate knowledge could help reduce 30-day readmissions.
Bourbeau raised concerns about the data sources behind many commercial AI tools. Content drawn from GOLD or clinical guidelines would be appropriate, but much of what these tools use is general knowledge base material, and its effect on patient outcomes remains unclear.
“We want the health care professional to get better at what they’re doing the best, and we want AI to help the health care professional at what AI should be doing the best,” said Bourbeau.
Bourbeau described 2 main areas GOLD has promoted: approaching COPD in terms of disease activity and stability and showing clinicians both the scope and the limitations of AI. He credited Alvar Agusti, MD, PhD, a member of the GOLD scientific committee, with leading the AI work.²
References